Stratec to sell loss-making Diatron MI unit and lifts 2026 margin outlook
German diagnostics maker Stratec will sell Diatron MI for 10 million euros plus earn-outs and now expects a higher adjusted EBIT margin for 2026, Reuters reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
German diagnostics systems provider Stratec told Reuters it will sell its loss-making Diatron MI business for 10 million euros plus earn-outs. The company will book a 44.1 million euro impairment in the third quarter and a 4 to 9 million euro deconsolidation loss in the fourth quarter.
Preliminary nine-month 2026 sales came in at 164.9 million euros, with an adjusted EBIT margin of 8.3%, both including the unit being divested. For full-year 2026, the company expects sales stable to slightly above 223.5 million euros on a constant-currency basis, and an adjusted EBIT margin of 13.0% to 15.0% after the divestment, up from a prior 10.0%.
Stratec has withdrawn its previous medium-term targets and will update them with the 2026 annual report.
why it matters
For markets, the bigger point is not the deal size but that a loss-making asset leaves the reported numbers and the margin outlook looks markedly stronger. According to Reuters, five of eight analysts rate the shares buy or strong buy, and three hold. The news mainly concerns Stratec shares.
market impact
Stratec shares: exit from a loss-making unit and higher margin guidance support the stock
- Stratec shares pressure up — loss-making unit leaves the group and margin guidance rises
tags
instruments
sources
- Germany's Stratec to sell unit Diatron MI; lifts 2026 adjusted operating margin — Reuters, 30 October 2026 at 22:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗